MedTrace Logo

Almond Dose Response Study.

NCT00507520 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2007-07-26

No results posted yet for this study

Summary

To assess the effects of almonds on coronary heart disease (CHD) risk factors (serum lipids, measurements of oxidative stress and nitric oxide production) when added to the diets of subjects with high cholesterol. Also, to assess whether the amount of almonds consumed (i.e. almond dose) decreases CHD risk factors in a dose dependent manner. We hypothesize that since almonds have been shown to reduce serum lipids, we believe they will also increase nitric oxide levels related to their high levels of arginine and reduce markers of oxidative stress related to their content of bioactive phenolics. We anticipate that a dose-dependent relationship will be observed resulting in greater reductions in risk factors for coronary heart disease when greater doses of almonds are consumed.

Conditions

Interventions

PROCEDURE

Full dose almonds

PROCEDURE

Half dose almonds+half dose muffin

PROCEDURE

Full dose whole wheat muffin

Sponsors & Collaborators

  • University of Toronto

    lead OTHER

Principal Investigators

  • David JA Jenkins, MD, PhD · University of Toronto, St. Michael's Hospital

  • Cyril WC Kendall, PhD · University of Toronto, St. Michael's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-12-31
Completion
2001-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00507520 on ClinicalTrials.gov